Niedźwiecki Sebastian, Piekarski Janusz, Szymańska Bożena, Pawłowska Zofia, Jeziorski Arkadiusz
Department of Surgical Oncology, Medical University of Lodz, Poland, ul. Paderewskiego 4, 93-509 Łódź, Poland.
Ginekol Pol. 2018;89(8):415-420. doi: 10.5603/GP.a2018.0071.
Breast cancer can be classified into five subtypes based on variations in the status of three hormonal receptors that are responsible for the cancer's heterogeneity: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These classifications influence the choice of therapies (either neoadjuvant or adjuvant), and the range of prognoses, from good (luminal A subtype) to poor (triple-negative cancers).
The aim of the study was to compare the serum concentration of selected miRNAs (miRNA-21, miRNA-10b, and miRNA-200c) between in two groups of breast cancer patients with differing ER, PR, and HER2 statuses.
The study was performed on two groups of patients. One group (TNBC) consisted of patients with triple-negative cancer, and the other group (ER(+)/PR(+)) was comprised of patients with positive ER and PR receptors.
The mean level of miRNA-200c was significantly higher in the ER(+)/PR(+) group than in the TNBC group (p < 0.05). No statistically significant difference was found between the two groups with regard to the mean levels of miRNA-21 or miRNA-10b.
The level of miRNA-200c was lower in triple-negative patients when compared with the levels in the study's ER/PR positive group.
乳腺癌可根据三种激素受体状态的变化分为五种亚型，这三种激素受体导致了癌症的异质性，即雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER2）。这些分类会影响治疗方案（新辅助治疗或辅助治疗）的选择以及预后范围，从良好（管腔A型亚型）到较差（三阴性癌症）。
本研究的目的是比较两组雌激素受体、孕激素受体和人表皮生长因子受体2状态不同的乳腺癌患者中所选微小RNA（miRNA-21、miRNA-10b和miRNA-200c）的血清浓度。
该研究在两组患者中进行。一组（三阴性乳腺癌组）由三阴性癌症患者组成，另一组（雌激素受体阳性/孕激素受体阳性组）由雌激素受体和孕激素受体阳性的患者组成。
雌激素受体阳性/孕激素受体阳性组中miRNA-200c的平均水平显著高于三阴性乳腺癌组（p < 0.05）。两组在miRNA-21或miRNA-10b的平均水平方面未发现统计学上的显著差异。
与研究中的雌激素受体/孕激素受体阳性组相比，三阴性患者中miRNA-200c的水平较低。
